Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 892 results for "astrazeneca"

AstraZeneca plc, Relypsa Inc Diverge on FDA Drug Rejection
Schaeffers Research

Overhang For Relypsa Remains, Morgan Stanley Says

A probable delay in the FDA approval of ZS-9, AstraZeneca plc's (ADR) (NYSE: AZN ) hyperkalaemia asset, could lend near-term upside to shares of Relypsa Inc (NASDAQ: RLYP ). Morgan Stanley's Andrew S Berens maintained an Equal-weight rating for the ... Benzinga.com, 5 hours ago
[x]  

255 images for astrazeneca

Bidness Etc, 3 hours ago
Livemint.com, 6 hours ago
Livemint.com, 6 hours ago
Bidness Etc, 2 days ago
American Banking News - Forex, 2 days ago
Invezz, 9 hours ago
Business Insider, 11 hours ago
Investor's Business Daily, 3 hours ago
4 Traders, 11 hours ago
Reuters UK, 9 hours ago
Nasdaq

AstraZeneca's Faslodex successful in late-stage breast cancer study as first-line treatment

Results from a Phase 3 clinical trial, FALCON, showed AstraZeneca's ( AZN -0.4%) FASLODEX (fulvestrant) was superior to Arimidex (anastrozole) in extending progression-free survival (PFS) in postmenopausal women with hormone receptor-positive (HR+) ...
 Seeking Alpha3 hours ago BRIEF-AstraZeneca announces positive results in breast cancer trial  Reuters UK12 hours ago AstraZeneca reports positive Phase III data for first-line Faslodex in advanced breast cancer  FirstWord Pharma4 hours ago AstraZeneca Fulvestrant Meets Primary Endpoint In Breast Cancer Late-stage Trial  Nasdaq7 hours ago
[x]  

AstraZeneca's Good Deal Turns Bad

health Is the Hedge Fund Heyday Over? Trade of the Week finance Feel the Burn Sad! energy Brakes On Online Lending finance Philips Lighting market value Looking Good deals Joint Share Exchange? MERGER TERMS tech Discount Sale ADRENALINE INVESTING ...
 Bloomberg2 hours ago
Pharmafile

European Ad Comm backs AstraZeneca's combo med for T2D

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) adopts a positive opinion recommending approval of AstraZeneca's ( AZN -0.7%) fixed-dose combination of saxagliptin and dapagliflozin for the treatment of adults ...
 Seeking Alpha4 hours ago EU regulator's advisory panel backs AstraZeneca diabetes drug  Yahoo! Finance6 hours ago EU panel backs AstraZeneca's combination therapy saxa/dapa for type 2 diabetes  FirstWord Pharma4 hours ago ASTRAZENECA : Key EU Committee Backs AstraZeneca Diabetes Drug  4 Traders6 hours ago
[x]  
Investor's Business Daily

AstraZeneca Potassium Drug Nixed; Rival Relypsa Up

Shares of big British pharma AstraZeneca ( AZN ) fell early Friday after the FDA rejected its potassium-lowering drug, while biotech Relypsa ( RLYP ) soared as its sole marketed drug is a rival product. AstraZeneca said the FDA had sent a ...
 Investor's Business Daily3 hours ago Relypsa Scores Big Win When Pharma Rival Flops at FDA  TheStreet.com7 hours ago AstraZeneca Potassium Drug Rejected; Rival Relypsa Roars  International Business Times4 hours ago
[x]  
Yahoo! Finance UK and Ireland

AstraZeneca plc (4.71%), Centrica plc (5.87%) and United Utilities Group plc (3.97%) are dividend WINNERS!

What dividend-generating stocks can sometimes lack in growth prospects, they will hopefully more than make upfor witha juicy income stream. So what do these three FTSE 100 stalwartsoffer? Patiencemay be rewarded Pharmaceutical play AstraZeneca ...
 Yahoo! Finance UK and Ireland6 hours ago
[x]  

AstraZeneca Remains Committed To Development Of ZS-9 Despite Letter From FDA

Shares of AstraZeneca plc (ADR) (NYSE: AZN ) were trading lower by more than 1.5 percent early Friday after the company confirmed it received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration relating to its New Drug ...
 Benzinga.com6 hours ago

Relypsa Surges 30% Following Setback From Rival AstraZeneca

Shares of Relypsa Inc (NASDAQ: RLYP ) surged higher by more than 30 percent early Friday morning on no corporate news or rumors. According to the TheStreet'sAdam Feuerstein, Relypisa scored a "big win" on Friday after its chief rival AstraZeneca ...
 Benzinga.com6 hours ago
Bidness Etc

FDA setback for AstraZeneca's hyperkalemia drug candidate ZS-9

AstraZeneca today announced that the US Food and Drug Administration has issued a Complete
 Pharma Letter3 hours ago Relypsa Inc: Brace for FDA Decision on AstraZeneca's ZS-9  Bidness Etc2 days ago Aurobindo Pharma ends 2% higher on FDA nod  India Infoline1 month ago

TOP NEWS: AstraZeneca Gets Good Breast Cancer Treatment Results

LONDON (Alliance News) - Drugmaker AstraZeneca PLC on Friday said the US Food & Drug Administration has issued a complete response letter on the new drug application made for sodium zirconium cyclosilicate, while also saying it secured good results ...
 4 Traders12 hours ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
Related Queries - astrazeneca
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less